Brigid Bio
Brigid Bio is pioneering the development of novel immunotherapies for the treatment of life-threatening and drug-resistant invasive fungal infections.
As a spinout from the University of Aberdeen, Brigid Bio leverages the world-class scientific expertise of two centres of excellence - Aberdeen Fungal Group and the Scottish Biologics Facility. Our experienced and accomplished team has a strong track record in commercialisation, enabling us to translate cutting-edge science into real-world solutions.
Our mission is to address the urgent demand for safer and more effective antifungal drugs, and ultimately improve clinical outcomes for high-risk patients. By advancing a first-in-class, biologic therapeutics, Brigid Bio is committed to transforming the standard of care for patients most vulnerable to invasive fungal diseases.
Invasive fungal infections (IFIs) lead to 3 million deaths globally each year. These infections are on the rise with the ever-increasing numbers of individuals at risk through advances in cancer therapies and other immunosuppressive regimens. Despite receiving best-available treatment, the mortality rate associated with invasive fungal infections remains alarmingly high, at 40-80% and has not improved in the last two decades.
In European ICU’s alone 79 cases of IFIs are diagnosed daily with 37% mortality at 30 days post diagnosis*. Invasive candidiasis and aspergillosis represent the most critical infections for patients in the ICU.*(Koehler et al., 2019)
"The WHO and CDC have categorised fungal infections as a serious threat to public health, highlighting the urgent need for novel therapeutics."
WHO-classified pathogens requiring urgent R&D attention
The CDC has declared Candida auris an urgent “superbug” due to its high mortality rate, multidrug resistance, and rapid spread in healthcare facilities.
When used in combination with chemotherapy and other immunosuppressive regimens, antifungals cause deleterious drug-drug interactions.
Due to the shared cellular structures and metabolic pathways in fungi and humans, certain antifungals have a high risk of liver and kidney toxicity in patients.
Emergence of multidrug resistant pathogens like Candida auris, Candida glabrata and Aspergillus fumigatus are resulting in treatment failures.
Current dosing frequency results in 1 in 7 candidemia patients being kept in hospitals for antifungal administration alone, leading to longer hospital stays and increased treatment costs.
Explore the key features that make our next-generation immunotherapy a game-changer in this critical area of unmet medical need.
Novel mechanism of action that selectively boosts immune system
Covers key fungal pathogens and drug-resistant Candida, Aspergillus and Rhizopus spp
Proven safety profile enables continuation of cancer therapy
Increased biological half-life enabling once a month vs daily/weekly dosing
Our patented drug discovery platform integrates proteomics and transcriptomics to identify key fungal cell wall markers critical for survival during infection and resistance. Using advanced antibody technologies and guided epitope selection, we have developed fully human monoclonal antibodies targeting the surface exposed regions of unique fungal cell wall proteins.
Our novel drug targets are fungal specific cell wall remodelling proteins with no human homologues.
Cell wall proteins are overexpressed upon antifungal challenge and in drug-resistant clinical isolates of key fungal pathogens, enhancing mAb binding when administered with standard of care.
The mAbs have proven efficacy in ‘clinically predictive’ mouse models of disseminated candidiasis, both in immunocompetent and immunocompromised mice models
Brigid Bio mAbs bind surface-exposed peptide epitopes identified by our proprietary drug discovery platform
Fully human therapeutic antibodies targeting unique cell wall proteins conserved in yeasts and moulds
(Candida & Aspergillus spp)
Brigid Bio mAbs are high-potency neutralising antibodies — far exceeding low-potency competitor sugar binders
Demonstrates enhanced binding when combined with standard of care antifungals – Echinocandins & Azoles
mAb binding increases in drug resistant strains - a unique advantage
Cell wall targets are overexpressed during macrophage engulfment boosting immune response
Executive Chairman
CEO & Co-Founder
CSO & Co-Founder
CTO & Co-Founder
CFO
Senior Scientist
Senior Scientist
CMC Advisor
Advisor Preclinical Dev
Advisor Regulatory
Advisor Clinical Trials
Clinical Advisor
February 24, 2026
Brigid Bio is excited to announce attendance at the 10th Antimicrobial Resistance (AMR) Conference in Basel 3-4th March 2026, a leading event for innovators in anti-infectives.
Read More
February 03, 2026
Brigid Bio was honoured to be invited to present at the symposium “Innovations in Antifungal Drug Development – An Industry-Academia Dialogue” organised by Leibniz-HKI, bringing together industry leaders and academic experts to advance innovation in antifungal therapeutics.
Read More
December 11 2025
Brigid Bio is delighted to announce its membership in the BEAM Alliance, the united voice of Small and Medium Enterprises (SMEs) innovating to combat Antimicrobial Resistance (AMR).
Read More
If you would like further information about our solution, please get
in contact with us.
We would love to hear from Oncologists, Infectious Disease
Consultants, and R&D specialists within the Biotech and Pharma
industries.
Brigid Bio, Liberty Building
Foresterhill Health Campus
Foresterhill Rd, Aberdeen AB25 2ZP